ICU
SeaStar Medical Holding Corporation Common Stock
stock NASDAQ

Just thought I’d share some personal good news and inspiration for anyone still paying on their student loans that it can be done
Paid off amount: $140K all federal
Time to pay off: \~18 months after training finished
Income: gross \~360K salary +240K overtime (ICU shift work) in VHCOL area
How I did it:. \~60K sign on bonus and the rest sweat equity.
Takeaway: I didn’t live/spend like a resident but definitely WORKED like a resident and it feels great to be debt free.
Next goal: Cutting back on the overtime a bit and saving for a home down payment

Look into ICU Delirium and contemplate which receptors are involved.  

This is exactly the kind of perspective that makes the current valuation seem so disconnected from reality.
Knowing that the CARPO data is already making waves in European rounds, especially with a group as respected as the Dutch Pancreatitis Study Group, really reinforces my thesis. A 100% reduction in respiratory failure is a massive shift in how these patients are managed in the ICU. It’s wild that a drug with that kind of clinical profile and Orphan Designation is being valued at $9M just because of a misunderstood trial halt in a different indication.
Really appreciate the insight from the clinical and European side. It definitely adds a lot of weight to why that H1 2026 pivotal trial design is such a huge catalyst.

Perspective from the Netherlands here. I have a friend that works closely with the Dutch Pancreatitis Study Group (PWN) with his uni, and they’ve been tracking CRAC channel inhibitors like Auxora for a while.
People in the US might not realize that in Europe, Acute Pancreatitis (AP) costs our healthcare systems roughly €10,000 per patient because we literally have no pharmacological tools to prevent progression to organ failure. We’ve been stuck with supportive care (fluids/nutrition) for decades.
The Phase 2b CARPO data published in The Lancet this February is a massive topic of discussion in our rounds. Seeing a 100% reduction in new-onset respiratory failure isn't just a statistical win, it’s a game changer for ICU capacity and patient survival. Here in the EU, Auxora already has Orphan Designation, which shows that regulators on this side of the pond are just as hungry for this as the FDA.

OP, consider it as a shield from high hospitalization costs. We all know how expensive hospitalization costs are sa Pinas. Just a week in ICU will already balloon to hundreds of thousands.
Health insurance is good if you can afford it but it's an annual cost that keeps on increasing depending on your parents' age and health. But unlike a hospital stock, it ends once you stop paying. For hospital stocks, it can be inherited by you, your kids, grandkids and so on.
If you do continue with this, also buy Maxicare prepaid card for emergencies. It's a good layer of protection as well. Look into it.